Navigation Links
New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
Date:8/12/2010

LOS ANGELES (Aug. 11, 2010) Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

The Phase II ovarian cancer study results as well as another Phase II trial in which Cedars-Sinai researchers also participated that evaluated the drug's effectiveness in the treatment of hereditary breast cancer were published in a recent issue of Lancet. The two trials showed similar levels of response to the genetically-targeted drug in both breast and ovarian cancers with BRCA mutations.

"These are significant new studies. Olaparib is the first single-agent, non-chemotherapy treatment to show benefit to patients with cancers that result from BRCA1 or BRCA2 gene mutations," said William Audeh, M.D., an oncologist specializing in cancer genetics at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute and first author on the ovarian cancer study "Until now, treatments for cancer have been selected based upon where in the body the cancer originated. These two studies suggest that it is the underlying genetic weakness of a cancer, not the organ of origin, that is the key to selecting effective therapy."

The first author of the breast cancer study and the principal investigator for both studies was Andrew Tutt, M.D., Breakthrough Breast Cancer Research Unit, King's College London School of Medicine.

Olaparib, a Poly ADP ribose polymerase (PARP) inhibitor made by AstraZeneca, represents a "targeted therapy" approach to cancer treatment anticancer drugs that interfere with specific pathways involved in cancer growth or survival. The PARP enzyme plays a role in DNA repair, including the repair of DNA damage from chemotherapy. Drugs that inhibit this enzyme appear to contribute to cancer cell death as well as increase their sensitivity to chemotherapy.

Of the 57 patients enrolled in the ovarian cancer study worldwide, 33 percent of participants showed a significant shrinkage in the size of their tumors, and in some cases, complete disappearance of their tumors. Toxicities from the drug were relatively mild, including nausea, fatigue and anemia.

"Women with advanced BRCA-mutated ovarian cancer have often been through several chemotherapy regimens, making it difficult to offer effective treatments," said Audeh. "PARP inhibitors may be a promising new option for this heavily 'pre-treated' population. "

Ovarian cancer is the fifth leading cause of cancer deaths among American women, with an estimated 21,550 new cases and 14,600 deaths in 2009. Approximately 10 percent of these cases have an inherited mutation in the BRCA 1 or 2 genes, the type of cases treated in this trial. Since it is often difficult to diagnose, many women present with advanced disease, which is especially challenging to treat.

"These PARP inhibitor studies represent a major change in the approach to treating cancer that will be reflected in future clinical trials," said Audeh. "While we studied Olaparib's clinical benefit in patients known to have specific genetic weaknesses in their cancer cells, it is hoped that this drug and others like it will be an effective tool to treat the underlying genetic defects found in all types of cancers."


'/>"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Service Foods Reduces its Carbon Footprint and Grows Sales
2. Health Care Reform Report Covers Uninsured, Reduces Costs
3. New cardiac CT technology drastically reduces patient radiation exposure
4. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
5. Targeted delivery of losartan reduces liver inflammation and scarring
6. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
7. Soccer reduces risk of falls and bone fractures
8. Pioneering treatment reduces disability in premature babies with serious brain hemorrhage
9. New drug candidate reduces blood lipids
10. PSA Test Reduces Prostate Cancer Deaths by 40%
11. New technique reduces tobacco smoke damage to lungs in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)... , June 23, 2016  The National ... has joined the health policy research organization as ... Romano , MD, senior vice president and chief ... company,s representative on the NPC Board of Directors. ... pleased that Mallinckrodt has joined us in support ...
Breaking Medicine Technology: